CA
NZ
UK
AU
IND
US
Section 351(k) of the Public Health Service Act is the abbreviated licensure route for biosimilars. An applicant must demonstrate that its product is highly similar to an already licensed reference biologic with no clinically meaningful differences, which typically requires analytical, non-clinical and clinical comparability …
A Biologics License Application amendment supplements a pending submission with additional information rather than starting a new one. Here the addition is 24-month open-label safety data. Longer-duration safety follow-up addresses durability of the safety profile, which is a common area of focus where a …
The USD 32 target sits roughly 15 per cent above the USD 27.84 closing price on the day. That is the arithmetic gap between the two figures and nothing more. A price target is one firm’s estimate of where a stock may trade over …
Two features define the deal as announced. The first is duration. Six months is a defined trial period rather than an open-ended commercial agreement, so the arrangement carries a review point built into it. The second is geography. Distribution rights apply to specific United …
A Form 10-Q is the interim periodic report that a domestic reporting company files for the first three quarters of its fiscal year. It carries unaudited financial statements and management discussion for the quarter. With two consecutive 10-Q filings outstanding, the most recent financial …
Overall survival was the measure on which superiority was reported. The announcement also stated that the secondary endpoints of progression free survival and objective response rate were met. Summit stated the result supports the broader clinical profile of ivonescimab ahead of a full data …
Scholar Rock Holding is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for patients with serious diseases. The company's lead program, apitegromab, targets myostatin inhibition for spinal muscular atrophy, alongside earlier-stage programs spanning FSHD and other indications, leveraging advances in biology …
Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological disorders, particularly epilepsy. The company's lead asset, RAP-219, is an investigational therapy targeting a novel mechanism for epilepsy treatment, leveraging advances in neuroscience and drug delivery to pursue improved efficacy …
Headquartered in Waltham, Massachusetts, Revvity was formed from the 2023 spin-off of PerkinElmer's diagnostics and life sciences businesses. The company operates through Diagnostics, Life Sciences, and Discovery Solutions segments, providing clinical diagnostic solutions including newborn screening and infectious disease testing, alongside research tools and …
Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for neurological and psychiatric disorders. The company's pipeline includes GlyphAllo for major depressive disorder, GlyphAgo for generalized anxiety disorder, and the preclinical Glyph2BLSD program targeting a non-hallucinogenic neuroplastogen, leveraging advances …
Please wait processing your request...